Abiraterone Acetate

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 3742 publications

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Journal: Minerva urology and nephrology

Published: June 23, 2026

Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancer.

Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancer.

Journal: Current medical research and opinion

Published: June 08, 2026

A CASE OF CASTRATION-RESISTANT PROSTATE CANCER ASSOCIATED WITH HEREDITARY BREAST-OVARIAN CANCER SYNDROME SHOWING LONG-TERM RESPONSE TO A POLY-ADP RIBOSE POLYMERASE INHIBITOR

A CASE OF CASTRATION-RESISTANT PROSTATE CANCER ASSOCIATED WITH HEREDITARY BREAST-OVARIAN CANCER SYNDROME SHOWING LONG-TERM RESPONSE TO A POLY-ADP RIBOSE POLYMERASE INHIBITOR

Journal: Hinyokika kiyo. Acta urologica Japonica

Published: May 26, 2026

Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making.

Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making.

Journal: Expert review of clinical pharmacology

Published: May 19, 2026

Intensification of radio-hormone therapy for prostate cancer

Intensification of radio-hormone therapy for prostate cancer

Journal: Revue medicale suisse

Published: May 18, 2026

Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.

Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.

Journal: Future oncology (London, England)

Published: May 11, 2026

Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.

Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.

Journal: JCO precision oncology

Published: May 11, 2026

Small Cell Transformation of Metachronous ALK + ve Lung and Prostatic Adenocarcinoma following Initial Response to Ceritinib and Androgen Deprivation Therapies and Metastases to Two Different Organs: Guidance through FDG-PET/CT and 68 Ga-PSMA-11 PET-CT and Biopsy-Immunohistochemistry Correlation.

Small Cell Transformation of Metachronous ALK + ve Lung and Prostatic Adenocarcinoma following Initial Response to Ceritinib and Androgen Deprivation Therapies and Metastases to Two Different Organs: Guidance through FDG-PET/CT and 68 Ga-PSMA-11 PET-CT and Biopsy-Immunohistochemistry Correlation.

Journal: World journal of nuclear medicine

Published: May 04, 2026

Low-Dose Versus Standard-Dose Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter Randomized Phase III Trial.

Low-Dose Versus Standard-Dose Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter Randomized Phase III Trial.

Journal: JCO global oncology

Published: April 23, 2026

Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer.

Real-world treatment patterns in metastatic castration-resistant prostate cancer progressing from metastatic hormone-sensitive prostate cancer.

Journal: Current medical research and opinion

Published: April 23, 2026

Insurance Disparity in Novel Hormonal Therapy Initiation in Patients With Metastatic Hormone-Sensitive Prostate Cancer: Medicare Advantage Versus Traditional Medicare.

Insurance Disparity in Novel Hormonal Therapy Initiation in Patients With Metastatic Hormone-Sensitive Prostate Cancer: Medicare Advantage Versus Traditional Medicare.

Journal: JCO oncology practice

Published: April 23, 2026

Modified monitoring of abiraterone acetate-induced hepatotoxicity in prostate cancer patients.

Modified monitoring of abiraterone acetate-induced hepatotoxicity in prostate cancer patients.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: April 20, 2026

Showing 1-12 of 3,742

Last Updated: 06/30/2026